SAN FRANCISCO — It’s hard to remember amid all the cocktail parties, panel sessions, networking meetings, and general glad-handing, but there’s an actual health care investor conference at the heart of the biotech industry’s gathering here each January.

Thousands of people flock to the J.P. Morgan Healthcare Conference but never actually step inside the conference’s home base at the Westin St. Francis Hotel on the western side of Union Square. They’re off doing other biotechy things. But about 9,000 people — executives from 450 biotech and drug companies plus investors and ne’er-do-wells like, ahem, journalists — do actually attend the conference.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • For Gilead, I hope someone would ask John Milligan for the status of Hrvoni and Epclusa approval and launch in china, when would Ovladi get on the country and regional lists, and what are the projections for revenue for all three drugs in 2018. Finally what about GLPG acquisitions in 2018.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy